29 August 2022
SHARE NOW
Allogeneic
Autologous
Cell Therapy
Gene Therapy
Ohad Karnieli, Founder and CEO of Adva Biotechnology, discusses the clinical potential for cell and gene therapies, as well as the gap that needs bridging in order to transform advanced therapies from scientific success to available cures.
In this short interview, Ohad discusses where we are in revolutionizing cancer treatment, as well as what gaps still need to be bridged in delivering advanced therapies to patients.
Hear more from Ohad at Advanced Therapies Europe – join his session at 13:30 on Wednesday 31st August, titled, ‘Exploring the Shift Towards Point-of-Care Automation & Decentralised Manufacturing.
This interview has been produced in partnership with Adva Biotechnology.
How are you enjoying this interview? Let us know your thoughts, here >>
While we have you…
We are continuously working to better optimize our content for you, our audience. Let us know how we’re doing by ticking the box below, or send us your feedback directly to team@phacilitate.com.
More like this
Scalable, xeno-free expansion of mesenchymal stem cells in a fixed-bed bioreactor
This case study showcases the successful expansion of mesenchymal stem cells (MSCs) using Rooster Bio’s xeno-free MSC platform in Univercells Technologies’ scale-X fixed-bed bioreactor. The collaboration highlights seamless process transfer, rapid cell attachment, optimized harvesting with high viability (>96%), and robust scalability from R&D to GMP manufacturing. Key innovations include predictive bioprocess monitoring with Scalia Vision and cost-effective solutions for advanced therapy manufacturing.
19 February 2025
Must-See Sessions at Advanced Therapies Week 2025: Ry Leahy, Head of Content, Phacilitate
Cell and gene therapies are set to revolutionize the future of medicine, but one of the major hurdles is the production of good quality cells cost-effectively and at scale
10 January 2025
